tropisetron (Navoban, Setrovel)
Jump to navigation
Jump to search
Introduction
Marketed by Novartis in Europe, Australia, New Zealand, Japan, South Korea & the Philippines as Navoban
Marketed in several Asian countries as Setrovel
Not available in the U.S.
Indications
- postoperative nausea & vomiting
- chemotheraoy-induced nausea & vomiting
- investigational uses
- Tanalgesia in fibromyalgia
- prevention of postoperative delirium?[2]*
* proof of effectiveness for prevention of postoperative delirium not provided
* study describes clinical trial not evidence of benefit[2]
Dosage
- 5 mg of tropisetron IV before anesthesia induction (postoperative delirium)
Mechanism of action
- serotonin 5-HT3 receptor antagonist
- may target alpha 7 nAChR
More general terms
Additional terms
References
- ↑ Wikipedia: Tropisetron https://en.wikipedia.org/wiki/Tropisetron
- ↑ 2.0 2.1 2.2 Sun Y, Lin D, Wang J et al Effect of Tropisetron on Prevention of Emergence Delirium in Patients After Noncardiac SurgeryA Trial Protocol. JAMA Netw Open.2020;3(10):e2013443. Oct 14, PMID: https://www.ncbi.nlm.nih.gov/pubmed/33052400 Free PMC article. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2771448